Alnylam and PBL Sign License Agreement for Baulcombe & Hamilton RNAi Patent
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Plant Bioscience Limited (PBL), a technology development and intellectual property (IP) management company, announced today that they have entered into a licensing agreement. PBL has granted Alnylam a world-wide, non-exclusive license to the Baulcombe patent (U.S. Patent No. 8,097,710) for use in the field of human therapeutics. Financial terms were not disclosed.
“We are pleased to expand our leading IP estate with a license to the Baulcombe patent,” said Laurence Reid, Ph.D., Senior Vice President and Chief Business Officer of Alnylam. “Alnylam continues to leverage its patent estate for the advancement of innovative medicines to patients and to enable the entire RNAi therapeutics field, with over 30 license agreements formed to date.”
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.